GOSS — Gossamer Bio, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1728117 ·
Last close
$9.88
Market Cap
$60.37M
52W High
$309.60
52W Low
$9.12
ADV30
263,160
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 9,238,000 | — | -26,074,000 | 16,900,000 | 76,867,000 | 41,148,000 | 170,896,000 |
| Mar 2026 | 16,955,000 | — | -44,866,000 | -46,664,000 | 128,899,000 | 41,028,000 | 290,382,000 |
| Dec 2025 | 13,799,000 | — | -46,040,000 | -47,238,000 | 172,249,000 | 37,732,000 | 295,009,000 |
| Sep 2025 | 13,294,000 | — | -41,638,000 | -48,221,000 | 208,820,000 | 8,933,000 | 291,153,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-170,263,000
Investing CF
$175,902,000
Financing CF
$6,433,000
CapEx
$-79,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.79
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,485,602,000
Inventory
—
Receivables
$9,252,000
ST Investments
$58,187,000
EBIT TTM
$-169,486,000
Pretax Income TTM
$-180,484,000
Interest Exp TTM
$10,998,000
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$53,286,000
EBITDA
$-158,596,992
Free Cash Flow
$-29,764,624
Enterprise Value
$48,608,568
Total Cash
$57,026,000
Total Debt
$40,068,000
Shares Out
6,110,584
Trailing EPS
$-52.80
Book Value
$-0.19
ROE
—
ROA
-62.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 48,471,000 | -163,253,000 | -170,370,000 | 172,249,000 | 295,009,000 | -122,760,000 | -171,266,000 |
| Dec 2024 | 114,701,000 | -59,919,000 | -56,528,000 | 315,292,000 | 285,800,000 | 29,492,000 | -3,468,000 |
| Dec 2023 | 0 | -173,759,000 | -179,817,000 | 311,916,000 | 249,147,000 | 62,769,000 | -159,158,000 |
| Dec 2022 | 0 | -218,528,000 | -229,378,000 | 272,450,000 | 260,373,000 | 12,077,000 | -187,032,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$55,537,000
NetIncome TTM
$-180,396,000
OpCashFlow TTM
—
Assets (Latest)
$128,899,000
Forward EPS
$-15.62
Max Pain — expiry 2028-01-21
max pain strike: $5.00 · spot: $9.88 · call oi: 5,576 · put oi: 0
Expected Move to 2028-01-21:
±$6.93
(70.14%) —
implied range
$2.95 –
$16.81
· ATM straddle on $7.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MREO | Mereo BioPharma Group plc | $59.92M | $0.38 | — |
| XLO | Xilio Therapeutics, Inc. | $59.29M | $9.01 | — |
| IBIO | iBio, Inc. | $59.16M | $0.92 | — |
| PLRX | PLIANT THERAPEUTICS, INC. | $61.92M | $1.00 | — |
| BOLD | Boundless Bio, Inc. | $58.69M | $2.58 | — |
News headlines (Yahoo Finance, 1h cache)
Gossamer Bio (GOSS) Stock Draws Fresh Price Target Split Before Seralutinib NDA
2026-10-01 23:12 · Yahoo
Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension
2026-09-23 20:01 · Yahoo
Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split
2026-09-11 12:00 · Yahoo
Assessment of the Pulmonary Arterial Hypertension (PAH) Market 2026-2036 Featuring United Therapeutics, Mochida Pharmaceutical, Johnson & Johnson, Merck, and Gossamer Bio
2026-09-08 08:31 · Yahoo
Gossamer Bio to Present at Cantor Global Healthcare Conference
2026-09-04 12:00 · Yahoo
Gossamer (GOSS) Announced Up to $250M of Financing, but Only $25M is Expected Upfront. Is the Runway Secure?
2026-08-27 19:59 · Yahoo
Gossamer Bio announces $250m in funding to advance seralutinib
2026-08-24 10:15 · Yahoo
Gossamer Bio Secures Up to $250 Million Private Placement to Fund Seralutinib Through Potential FDA Approval
2026-08-21 13:49 · Yahoo
Gossamer Bio Agrees to Up to $250 Million Private Placement; Shares Rise Pre-Bell
2026-08-21 12:34 · Yahoo
Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval
2026-08-21 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.